Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ellmark

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
European Journal of Immunology|November 23, 2016
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancerLuuk van Hooren, Linda C Sandin, Igor Moskalev, et al.
Cancer Immunology, Immunotherapy : CII|September 15, 2017
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regressionJonathan P O Hebb, Adriane R Mosley, Felipe Vences-Catalán, et al.
Cancer Medicine|March 17, 2022
Transcriptional profiling demonstrates altered characteristics of CD8<sup>+</sup> cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemiaMilad Abolhalaj, Viktor Sincic, Henrik Lilljebjörn, et al.
Biomaterials|June 13, 2012
Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticlesSissela Broos, Linda C Sandin, Jenny Apel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunitySara M Mangsbo, Sissela Broos, Erika Fletcher, et al.
Proteomics|June 6, 2008
Detection of pancreatic cancer using antibody microarray-based serum protein profilingJohan Ingvarsson, Christer Wingren, Anders Carlsson, et al.
Cells|October 13, 2023
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal AntibodyHampus Andersson, Aastha Sobti, David Gomez Jimenez, et al.
International Journal of Cancer|January 22, 2019
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignanciesSandra M M Irenaeus, Dorte Nielsen, Peter Ellmark, et al.
Cancer Immunology, Immunotherapy : CII|October 5, 2023
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1Karin Enell Smith, Sara Fritzell, Anneli Nilsson, et al.
Cells|June 19, 2024
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular SubtypesViktor Sincic, Ken F Arlenhold, Sarah Richtmann, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
European Journal of Immunology|November 23, 2016
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancerLuuk van Hooren, Linda C Sandin, Igor Moskalev, et al.
Cancer Immunology, Immunotherapy : CII|September 15, 2017
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regressionJonathan P O Hebb, Adriane R Mosley, Felipe Vences-Catalán, et al.
Cancer Medicine|March 17, 2022
Transcriptional profiling demonstrates altered characteristics of CD8<sup>+</sup> cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemiaMilad Abolhalaj, Viktor Sincic, Henrik Lilljebjörn, et al.
Biomaterials|June 13, 2012
Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticlesSissela Broos, Linda C Sandin, Jenny Apel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunitySara M Mangsbo, Sissela Broos, Erika Fletcher, et al.
Proteomics|June 6, 2008
Detection of pancreatic cancer using antibody microarray-based serum protein profilingJohan Ingvarsson, Christer Wingren, Anders Carlsson, et al.
Cells|October 13, 2023
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal AntibodyHampus Andersson, Aastha Sobti, David Gomez Jimenez, et al.
International Journal of Cancer|January 22, 2019
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignanciesSandra M M Irenaeus, Dorte Nielsen, Peter Ellmark, et al.
Cancer Immunology, Immunotherapy : CII|October 5, 2023
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1Karin Enell Smith, Sara Fritzell, Anneli Nilsson, et al.
Cells|June 19, 2024
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular SubtypesViktor Sincic, Ken F Arlenhold, Sarah Richtmann, et al.
Pageof 4